Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766726 · ClinicalTrials.gov registry record
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 33
- Enrollment target
NCT01766726: Completed study, sponsored by Massachusetts General Hospital.
NCT01766726 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01766726 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The main aims of this study are to determine whether: a) ART-naïve HIV+ subjects have increased artherosclerotic plaque inflammation/vulnerability, b) newly-initiated QUAD/Stribild therapy will decrease plaque inflammation/vulnerability in these subjects, and c) QUAD/Stribild therapy will improve indices of immune dysregulation and lipid dysfunction as a mechanism of improved plaque inflammation/vulnerability. Parameters of lipid and immune function will also be assessed in healthy control subjects, for comparison.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766726
The ClinicalTrials.gov registry entry for NCT01766726 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01766726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01766726 about?
NCT01766726 is a clinical study titled "Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients". The main aims of this study are to determine whether: a) ART-naïve HIV+ subjects have increased artherosclerotic plaque inflammation/vulnerability, b) newly-initiated QUAD/Stribild therapy will decrease plaque inflammation/vulnerability in these subjects, and c) QUAD/Stribild therapy will improve in...
What is the current status of trial NCT01766726?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2012-12. Estimated completion is 2016-01.
Who is sponsoring clinical trial NCT01766726?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.